Viatris stock price forecast economic indicators suggest Viatris

Economic indicators suggest Viatris stock price forecast could outperform broader pharma benchmarks if FDA approvals for pipeline products stay on schedule. Thursday, Viatris Inc (NASDAQ: VTRS ) reported first-quarter EPS of $0.67, which is in line with the consensus . The stock is down significantly so far in 2025. In December 2024, the FDA issued a warning letter and import alert for Viatris' Indore manufacturing facility in India due to regulatory compliance issues. Wall Street consensus on Viatris stock price forecast is moderately positive, driven by patent expirations opening up new markets. Average analyst price target currently trends at $11.